Selected research
Industry Research
Autoimmune Disease Drug Industry Research Report 2026
Market perspective
The global Autoimmune Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Autoimmune Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Autoimmune Disease Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Autoimmune Disease Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Autoimmune Disease Drug include Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Amgen, AbbVie, Bristol-Myers Squibb, Biogen and AstraZeneca plc and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Autoimmune Disease Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Autoimmune Disease Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Autoimmune Disease Drug Market by Company
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Amgen
AbbVie
Bristol-Myers Squibb
Biogen
AstraZeneca plc
Abbott Laboratories
Autoimmune Disease Drug Segment by Type
NSAIDs
Interferons
Antihyperglycemics
Anti-Inflammatory
Others
Autoimmune Disease Drug Segment by Application
Psoriasis
Inflammatory Bowel Disease
Rheumatoid Arthritis
Lupus
Multiple Sclerosis
Type 1 Diabetes
Others
Autoimmune Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Autoimmune Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Autoimmune Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- NSAIDs
- Interferons
- Antihyperglycemics
- Anti-Inflammatory
- Others
Applications
- Psoriasis
- Inflammatory Bowel Disease
- Rheumatoid Arthritis
- Lupus
- Multiple Sclerosis
- Type 1 Diabetes
- Others
Companies covered
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Amgen
- AbbVie
- Bristol-Myers Squibb
- Biogen
- AstraZeneca plc
- Abbott Laboratories
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Autoimmune Disease Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 NSAIDs
- 2.2.3 Interferons
- 2.2.4 Antihyperglycemics
- 2.2.5 Anti-Inflammatory
- 2.2.6 Others
- 2.3 Autoimmune Disease Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Psoriasis
- 2.3.3 Inflammatory Bowel Disease
- 2.3.4 Rheumatoid Arthritis
- 2.3.5 Lupus
- 2.3.6 Multiple Sclerosis
- 2.3.7 Type 1 Diabetes
- 2.3.8 Others
- 2.4 Assumptions and Limitations
3 Autoimmune Disease Drug Breakdown Data by Type
- 3.1 Global Autoimmune Disease Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Autoimmune Disease Drug Forecasted Market Size by Type (2027-2032)
4 Autoimmune Disease Drug Breakdown Data by Application
- 4.1 Global Autoimmune Disease Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Autoimmune Disease Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Autoimmune Disease Drug Market Perspective (2021-2032)
- 5.2 Global Autoimmune Disease Drug Growth Trends by Region
- 5.2.1 Global Autoimmune Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Autoimmune Disease Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Autoimmune Disease Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Autoimmune Disease Drug Market Dynamics
- 5.3.1 Autoimmune Disease Drug Industry Trends
- 5.3.2 Autoimmune Disease Drug Market Drivers
- 5.3.3 Autoimmune Disease Drug Market Challenges
- 5.3.4 Autoimmune Disease Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Autoimmune Disease Drug Players by Revenue
- 6.1.1 Global Top Autoimmune Disease Drug Players by Revenue (2021-2026)
- 6.1.2 Global Autoimmune Disease Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Autoimmune Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Autoimmune Disease Drug Head Office and Area Served
- 6.4 Global Autoimmune Disease Drug Players, Product Type & Application
- 6.5 Global Autoimmune Disease Drug Manufacturers Established Date
- 6.6 Global Autoimmune Disease Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Autoimmune Disease Drug Market Size (2021-2032)
- 7.2 North America Autoimmune Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Autoimmune Disease Drug Market Size by Country (2021-2026)
- 7.4 North America Autoimmune Disease Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Autoimmune Disease Drug Market Size (2021-2032)
- 8.2 Europe Autoimmune Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Autoimmune Disease Drug Market Size by Country (2021-2026)
- 8.4 Europe Autoimmune Disease Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Autoimmune Disease Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Autoimmune Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Autoimmune Disease Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Autoimmune Disease Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Autoimmune Disease Drug Market Size (2021-2032)
- 10.2 South America Autoimmune Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Autoimmune Disease Drug Market Size by Country (2021-2026)
- 10.4 South America Autoimmune Disease Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Autoimmune Disease Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Autoimmune Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Autoimmune Disease Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Autoimmune Disease Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.1.4 Roche Autoimmune Disease Drug Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Eli Lilly
- 12.2.1 Eli Lilly Company Information
- 12.2.2 Eli Lilly Business Overview
- 12.2.3 Eli Lilly Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.2.4 Eli Lilly Autoimmune Disease Drug Product Portfolio
- 12.2.5 Eli Lilly Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.3.4 Pfizer Autoimmune Disease Drug Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GlaxoSmithKline
- 12.4.1 GlaxoSmithKline Company Information
- 12.4.2 GlaxoSmithKline Business Overview
- 12.4.3 GlaxoSmithKline Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.4.4 GlaxoSmithKline Autoimmune Disease Drug Product Portfolio
- 12.4.5 GlaxoSmithKline Recent Developments
- 12.5 Amgen
- 12.5.1 Amgen Company Information
- 12.5.2 Amgen Business Overview
- 12.5.3 Amgen Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.5.4 Amgen Autoimmune Disease Drug Product Portfolio
- 12.5.5 Amgen Recent Developments
- 12.6 AbbVie
- 12.6.1 AbbVie Company Information
- 12.6.2 AbbVie Business Overview
- 12.6.3 AbbVie Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.6.4 AbbVie Autoimmune Disease Drug Product Portfolio
- 12.6.5 AbbVie Recent Developments
- 12.7 Bristol-Myers Squibb
- 12.7.1 Bristol-Myers Squibb Company Information
- 12.7.2 Bristol-Myers Squibb Business Overview
- 12.7.3 Bristol-Myers Squibb Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.7.4 Bristol-Myers Squibb Autoimmune Disease Drug Product Portfolio
- 12.7.5 Bristol-Myers Squibb Recent Developments
- 12.8 Biogen
- 12.8.1 Biogen Company Information
- 12.8.2 Biogen Business Overview
- 12.8.3 Biogen Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.8.4 Biogen Autoimmune Disease Drug Product Portfolio
- 12.8.5 Biogen Recent Developments
- 12.9 AstraZeneca plc
- 12.9.1 AstraZeneca plc Company Information
- 12.9.2 AstraZeneca plc Business Overview
- 12.9.3 AstraZeneca plc Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.9.4 AstraZeneca plc Autoimmune Disease Drug Product Portfolio
- 12.9.5 AstraZeneca plc Recent Developments
- 12.10 Abbott Laboratories
- 12.10.1 Abbott Laboratories Company Information
- 12.10.2 Abbott Laboratories Business Overview
- 12.10.3 Abbott Laboratories Revenue in Autoimmune Disease Drug Business (2021-2026)
- 12.10.4 Abbott Laboratories Autoimmune Disease Drug Product Portfolio
- 12.10.5 Abbott Laboratories Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst